← Eichor
Study identifier: NCT06924944 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Outcomes of Bilateral Clareon Vivity in Post-Refractive Patients

Condition: Correction Vision Surgery · Cataract Surgery  ·  Sponsor: Utah Eye Centers

PhaseN/A
Planned participants35
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Millions of people have undergone laser vision correction surgery and are motivated to continue with spectacle independence as they develop presbyopia (gradual loss of your eyes' ability to focus on nearby objects)and cataract. However, having a history of refractive surgery, poses challenges in the selection of the IOLs and can lead to visual outcomes that are unpredictable. Data from an international registry and single prospective study show that Vivity IOL provided effective distance, intermediate and near vision in eyes with previous LASIK with minimal effects on day vision associated with the surgery. The purpose of this study is to evaluate the clinical outcomes of post-myopic refractive surgery patients implanted with the Clareon Vivity/Vivity Toric lenses

This description comes directly from the study's public registry record.

Talk to the study team

Rachel Buchanan  ·  8014099873  ·  rbuchanan@utaheyecenters.com

Always discuss trial participation with your own doctor first.

Locations (1)

Utah Eye CentersOgden, Utah, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06924944